CRB-602

N/A

Report date: 2022/07/27 14:08:50

Base Information

Drug NameCRB-602
Drug Alias NameCRB-602
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionIntegrin alpha-V/beta-6 antagonistsAnti-integrin alpha V/beta 8
TargetsIntegrin alpha-V/beta-6integrin alpha V/beta 8
Therapy Area/IndicationsSolid tumoursFibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCorbus Pharmaceuticals Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesCorbus Pharmaceuticals Holdings Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursFibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A